Business Context and Reporting Period
Company: Aastrom Biosciences, Inc. (Note: Request metadata listed "Vericel Corp," but the filing text identifies the registrant as Aastrom Biosciences, Inc.)
Reporting Period: Quarterly Report on Form 10-Q for the period ended December 31, 2002.
Business Stage: Development-stage company focused on human cell-based therapies, specifically the AastromReplicell System for ex vivo cell production. The company has never been profitable and relies on equity financing and grants.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2002 | Six Months Ended Dec 31, 2002 |
|---|---|---|
| Total Revenues | $296,000 | $389,000 |
| Net Loss | $(2,287,000) | $(4,739,000) |
| Net Loss Per Share (Basic/Diluted) | $(0.05) | $(0.10) |
| Cash and Cash Equivalents (Dec 31, 2002) | $6,760,000 | |
| Accumulated Deficit (Inception to Dec 31, 2002) | $(98,536,000) | |
| Net Cash Used in Operating Activities (6 months) | $(4,806,000) |
Revenue Breakdown (6 months): Product sales and rentals ($168,000), Grants ($211,000), and R&D agreements ($10,000).
Expense Breakdown (6 months): R&D ($2,817,000), SG&A ($2,015,000), Cost of product sales ($370,000).
Material Changes vs. Prior Period
- Revenue: Total revenue for the six months ended Dec 31, 2002, decreased to $389,000 from $418,000 in the prior year period. This was driven by a decrease in grant revenues, partially offset by a significant increase in product sales and rentals ($168,000 vs. $80,000) due to increased marketing in Europe.
- Expenses: Total costs and expenses increased to $5,202,000 (6 months) from $4,559,000 in the prior year. Increases were seen in R&D, SG&A, and cost of product sales. The cost of product sales included a $259,000 charge for obsolete and excess inventory reserves.
- Liquidity: Cash and cash equivalents decreased by $2,845,000 from June 30, 2002 ($8,605,000) to December 31, 2002 ($6,760,000), primarily due to operating cash burn of $4.8 million, partially offset by $1.99 million in equity financing.
Guidance, Outlook, Risks, and Contingencies
- Liquidity Outlook: Management expects available cash and financing to fund operations into the first quarter of fiscal year 2004 (ending September 30, 2003). The company anticipates needing significant additional funding prior to July 2003 to avoid substantial reductions in operations.
- Financing: The company entered a common stock purchase agreement with Fusion Capital Fund II, LLC in October 2002, allowing for up to $12 million in purchases over 24 months. As of Dec 31, 2002, no shares had been issued under this agreement, though $307,000 was raised subsequently in January 2003.
- Supply Chain Risk: A key manufacturer, Plexus, elected to terminate its Manufacturing Supply Agreement effective February 2004. Aastrom is negotiating with a new supplier. Additionally, another supplier, Moll, filed for Chapter 11 bankruptcy in September 2002, though supply has not been significantly impacted to date.
- Regulatory and Market Risk: The company faces risks regarding FDA approval for its lead product (AastromReplicell System) and potential delisting from Nasdaq if the stock price does not meet the $1.00 minimum bid price requirement. The company is seeking an extension of the grace period.
- Profitability: The company does not expect to generate positive cash flow from operations for at least the next two to three years.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $6.76 million cash balance to fund operations through September 2003 given the $4.8 million operating cash burn in the last six months.
- Financing Progress: Confirm the status of the Fusion Capital agreement and any new equity raises required before July 2003 to prevent operational curtailment.
- Supply Chain Continuity: Assess the finalization of the new manufacturing agreement to replace Plexus and the stability of the Moll supply chain post-bankruptcy.
- Inventory Valuation: Review the $259,000 inventory write-down and the methodology for future reserves given the limited sales history.
- Nasdaq Compliance: Monitor the stock price relative to the $1.00 minimum bid requirement and the status of the SEC approval for the Nasdaq grace period extension.